RESULTS	At 12 months , the belatacept LI arm demonstrated a numerically higher rate of patients surviving with a functioning graft ( 90.4 % MI [ 103 of 114 ] , 92.8 % LI [ 90 of 97 ] , and 80.8 % cyclosporine [ 101 of 125 ] ) , and fewer serious adverse events than cyclosporine or MI patients .\